Pancreatic cancer is an extremely lethal malignancy. On average, patients who are diagnosed with pancreatic cancer succumb to the disease within 6 months. Research is the only way to defeat pancreatic cancer. My lab is making progress toward finding a cure by detecting the disease earlier and designing novel therapeutic approaches.
David Tuveson’s laboratory uses murine and human models of pancreatic cancer to explore the fundamental biology of malignancy and thereby identify new diagnostic and treatment strategies. The lab’s approaches run the gamut from designing new model systems of disease to developing new therapeutic and diagnostic approaches for rapid evaluation in preclinical and clinical settings. The lab’s studies make use of organoid cultures—three-dimensional cultures of normal or cancerous epithelia—as ex vivo models to probe cancer biology. Current projects in the lab explore changes in redox metabolism associated with pancreatic cancer tumorigenesis, dissect signaling by the Ras oncogene, discover new biomarkers of early pancreas cancer, and identify mechanisms of cross-talk between pancreatic cancer cells and the tumor stroma. Novel treatment approaches suggested by these studies are then tested by performing therapeutic experiments in mouse models. To dissect molecular changes associated with pancreatic tumorigenesis, the Tuveson lab has generated a large collection of human patient-derived organoid models. By measuring the therapeutic sensitivities of patient-derived organoids, the lab is working to identify novel strategies to treat patients as well as markers of therapeutic response. The Tuveson Laboratory maintains strong links to clinical research, and the ultimate goal is confirmation of preclinical findings in early-phase trials. Collectively, the lab’s bench-to-bedside approach is codified as the “Cancer Therapeutics Initiative,” and this initiative will provide these same approaches to the entire CSHL cancer community.
Dr. Tuveson serves as Director of the Cold Spring Harbor Laboratory Cancer Center and the Chief Scientist for the Lustgarten Foundation.
Turning cells against pancreatic cancer
October 26, 2018
Cold Spring Harbor, NY — Pancreatic cancer has a grim prognosis. It is usually detected after the disease has spread, and chemotherapy tends to do little to slow the cancer’s growth. Even with treatment, most patients live only about six months after they are diagnosed with the disease. Researchers in Professor David Tuveson’s laboratory at...
Nation’s cancer centers endorse HPV vaccination
June 8, 2018
Cold Spring Harbor Laboratory joins NCI-designated cancer centers in endorsing the goal of eliminating HPV-related cancers Bruce Stillman, Ph.D., President and CEO of Cold Spring Harbor Laboratory, and David Tuveson, M.D., Ph.D., Director of CSHL’s NCI-designated Cancer Center, today joined with the leaders of other institutions nationwide in endorsing the following statement regarding revised recommendations...
Organoid profiling personalizes treatments for pancreatic cancer
May 31, 2018
A new tool to select the treatments most likely to work in specific patients Cold Spring Harbor, NY — Patient-derived organoids, hollow spheres of cells cultured from tumors, can quickly and accurately predict how patients with pancreatic cancer respond to a variety of treatments, facilitating a precision-medicine approach to the deadly disease. The ability to...
David Tuveson elected to the AACR Board of Directors
April 13, 2018
Pancreatic cancer is a disease that takes the lives of over 40,000 Americans a year, one that CSHL Professor Dr. David Tuveson has spent his career studying. His extensive work identifying new diagnostic and treatment strategies for this highly lethal cancer has been honored by the American Association of Cancer Research (AACR), which has named...
Halfway around the world, a reunion of friends opens door to a cancer discovery
August 31, 2017
LabDish blog After interviewing for a position in a pancreatic cancer lab at Cold Spring Harbor Laboratory, 7,000 miles from his hometown in South Korea, Chang-il Hwang did what many of us would: he posted about it on Facebook. Little did he know that he was rekindling a friendship that would pave the way to...
CSHL to lead international team developing next-generation organoid cancer research
May 11, 2017
Cold Spring Harbor Laboratory (CSHL) has been awarded a research subcontract by Leidos Biomedical Research to lead a Cancer Model Development Center
Newly discovered mutations impair key cell pathways in pancreatic cancer
May 8, 2017
Cold Spring Harbor, NY — By closely studying a part of the human genome that has not yet been carefully scrutinized in studies of cancer, researchers at Cold Spring Harbor Laboratory (CSHL) have found important new clues to the development of pancreatic cancer. The researchers looked exclusively at small segments of DNA called promoters in...
Discovery of distinct cell subtypes around tumors helps explain why pancreatic cancer is so hard to treat
February 23, 2017
Cold Spring Harbor, NY — Researchers have moved an important step closer to understanding why pancreatic cancer is so hard to treat. With a median survival of only 6 months and a 5-year survival rate of about 8%, patients tend to be diagnosed when the disease has already spread to other parts of the body—this...
CSHL joins NCI-designated cancer centers in endorsing updated HPV vaccination recommendations
January 11, 2017
Bruce Stillman, Ph.D., President and CEO of Cold Spring Harbor Laboratory, and David Tuveson, M.D., Ph.D., Director of CSHL’s NCI-designated Cancer Center, today joined with the leaders of other institutions nationwide in endorsing the following statement regarding revised recommendations concerning the HPV (human papillomavirus) vaccine: Recognizing low rates of human papillomavirus (HPV) vaccinations as a...
Dr. David Tuveson named Director, NCI-Designated Cancer Center at Cold Spring Harbor Laboratory
November 29, 2016
Cold Spring Harbor, NY — David Tuveson, M.D., Ph.D., will succeed Dr. Bruce Stillman as Director of the Cold Spring Harbor Laboratory (CSHL) Cancer Center. Dr. Stillman has served as director of the Laboratory’s National Cancer Institute (NCI)-designated Cancer Center for 25 years, shepherding the Center through five highly successful renewals and a overseeing significant...
Jacobetz, M. A. and Chan, D. S. and Neesse, A. and Bapiro, T. E. and Cook, N. and Frese, K. K. and Feig, C. and Nakagawa, T. and Caldwell, M. E. and Zecchini, H. I. and Lolkema, M. P. and Jiang, P. and Kultti, A. and Thompson, C. B. and Maneval, D. C. and Jodrell, D. I. and Frost, G. I. and Shepard, H. M. and Skepper, J. N. and Tuveson, D. A. (2013) Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut, 62(1) pp. 112-20.
Perez-Mancera, P. A. and Rust, A. G. and van der Weyden, L. and Kristiansen, G. and Li, A. and Sarver, A. L. and Silverstein, K. A. and Grutzmann, R. and Aust, D. and Rummele, P. and Knosel, T. and Herd, C. and Stemple, D. L. and Kettleborough, R. and Brosnan, J. A. and Li, A. and Morgan, R. and Knight, S. and Yu, J. and Stegeman, S. and Collier, L. S. and ten Hoeve, J. J. and de Ridder, J. and Klein, A. P. and Goggins, M. and Hruban, R. H. and Chang, D. K. and Biankin, A. V. and Grimmond, S. M. and Wessels, L. F. and Wood, S. A. and Iacobuzio-Donahue, C. A. and Pilarsky, C. and Largaespada, D. A. and Adams, D. J. and Tuveson, D. A. (2012) The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma. Nature, 486(7402) pp. 266-70.
Cook, N. and Frese, K. K. and Bapiro, T. E. and Jacobetz, M. A. and Gopinathan, A. and Miller, J. L. and Rao, S. S. and Demuth, T. and Howat, W. J. and Jodrell, D. I. and Tuveson, D. A. (2012) Gamma secretase inhibition promotes hypoxic necrosis in mouse pancreatic ductal adenocarcinoma. J Exp Med, 209(3) pp. 437-44.
Frese, K. K. and Neesse, A. and Cook, N. and Bapiro, T. E. and Lolkema, M. P. and Jodrell, D. I. and Tuveson, D. A. (2012) nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer. Cancer Discov, 2(3) pp. 260-9.
DeNicola, G. M. and Karreth, F. A. and Humpton, T. J. and Gopinathan, A. and Wei, C. and Frese, K. and Mangal, D. and Yu, K. H. and Yeo, C. J. and Calhoun, E. S. and Scrimieri, F. and Winter, J. M. and Hruban, R. H. and Iacobuzio-Donahue, C. and Kern, S. E. and Blair, I. A. and Tuveson, D. A. (2011) Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature, 475(7354) pp. 106-9.Additional materials of the author at
CSHL Institutional Repository